Articles
Volume 14 Supplement 1
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Meeting abstracts
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany
28-30 June 2013
Edited by John C Burnett Jr, Franz Hofmann, Kazuwa Nakao, Harald HHW Schmidt and Johannes-Peter Stasch
Publication of this supplement has been fully funded by Bayer Pharma AG. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
|
Oral presentation
Chronic natriuretic peptide protein therapeutics Horng H Chen, Alessandro Cataliotti, John C Burnett BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O1 (29 August 2013) |
|
Oral presentation
Loek van Heerebeek, Nazha Hamdani, Inês Falcão-Pires, Adelino F Leite-Moreira, Mark PV Begieneman, Jean GF Bronzwaer, Jolanda van der Velden, Ger JM Stienen, Gerrit J Laarman, Aernout Somsen, Freek WA Verheugt, Hans WM Niessen, Walter J Paulus BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O2 (29 August 2013) |
|
Oral presentation
Abstract not submitted for publication BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O3 (29 August 2013) |
|
Oral presentation
Lessons from tissue-specific KO of CNP/GC-B system - everlasting challenge to clinical application Kazuwa Nakao, Koitiro Kuwahara, Hiroaki Yasoda, Goro Katuura, Kazuhiro Nakao, Kazumasa Nakao, Yui Yamasita BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O4 (29 August 2013) |
|
Oral presentation
What have genome-wide association studies taught us about cGMP and blood pressure regulation? Christopher Newton-Cheh BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O5 (29 August 2013) |
|
Oral presentation
Genetic variants in guanylyl cyclase and phoshodiesterase affecting coronary disease risk Heribert Schunkert BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O6 (29 August 2013) |
|
Oral presentation
Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics Valentina Cannone, Paul M McKie, Angelo Cefalu, Davide Noto, Giovanni Cavera, Michele Pagano, Michelangelo Sapienza, Timothy M Olson, Denise M Heublein, Christopher G Scott, Kent R Bailey, Maurizio Averna, John C Burnett BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O7 (29 August 2013) |
|
Oral presentation
Genetic modifiers of hypertension in sGC-deficient mice Emmanuel Buys BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O8 (29 August 2013) |
|
Oral presentation
Pulmonary vascular adaptation to high-altitude living Martin Wilkins BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O9 (29 August 2013) |
|
Oral presentation
MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide Pankaj Arora, Connie Wu, Donald B Bloch, Brandi N Davis-Dusenbury, Ester Spagnolli, Akiko Hata, Sara Vandenwijngaert, Melissa Swinnen, Stefan Janssens, Emmanuel S Buys, Kenneth D Bloch, Christopher Newton-Cheh, Thomas J Wang BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O10 (29 August 2013) |
|
Oral presentation
cGMP kinase: past, presence and future Franz Hofmann, Florian Loga, Katrin Domes, Enrico Patrucco, Jörg W Wegener BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O11 (29 August 2013) |
|
Oral presentation
Conformational changes involved in sGC activation Michael A Marletta, Eric Underbakke, Melody G Campbell, Bridget Carragher, Clinton S Potter BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O12 (29 August 2013) |
|
Oral presentation
A twenty year journey to understand how ATP activates guanylyl cyclase A and B Lincoln R Potter BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O13 (29 August 2013) |
|
Oral presentation
Franziska Seeger, Elsa D Garcin BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O14 (29 August 2013) |
|
Oral presentation
Opher Gileadi, Charles Allerston, Frank von Delft BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O15 (29 August 2013) |
|
Oral presentation
Structures of human PKG reveal cGMP-selectived activation mechanisms Gilbert Y Huang, Jeong J Kim, Albert S Reger, Robin Lorenz, Eui-Whan Moon, Chi Zhao, Darren E Casteel, Daniela Bertinetti, Bryan VanSchouwen, Rajeevan Selvaratnam, James W Pflugrath, Banumathi Sankaran, Giuseppe Melacini, Friedrich W Herberg, Choel Kim BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O16 (29 August 2013) |
|
Oral presentation
Mary Struthers, Subharekha Raghavan, Ronald Kim, Christopher Sinz, Sophie Roy, Michael Mendelsohn BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O17 (29 August 2013) |
|
Oral presentation
Mechanisms driving heme insertion into apo-sGC during its maturation in cells Dennis Stuehr, Arnab Ghosh, Anindya Sarkar, Yue Dai BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O18 (29 August 2013) |
|
Oral presentation
Redox signalling by protein kinase G Iα in cardiovascular physiology and pathology Philip Eaton BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O19 (29 August 2013) |
|
Oral presentation
New mechanisms of normoxic and hypoxic cGMP signalling mediated by the nitrite anion Hunter Champion BMC Pharmacology and Toxicology 2013, 14(Suppl 1):O20 (29 August 2013) |
